Fukushima T, et al. - In this phase II study, researchers assessed the efficacy and safety of cisplatin/pemetrexed combined with 15 mg/kg of bevacizumab followed by pemetrexed/bevacizumab maintenance therapy as first-line chemotherapy in patients with advanced or metastatic epidermal growth factor receptor (EGFR)-wild type non-squamous non-small cell lung cancer (NSCLC) aged < 75 years old. Favorable efficacy of the combination of cisplatin/pemetrexed/bevacizumab followed by pemetrexed/bevacizumab maintenance therapy was seen in patients with EGFR-wild type non-squamous NSCLC. Toxicity profiles were managable. The reported grade 3 adverse events included neutropenia (14%), nausea (10%), anorexia (18%), and hypertension (8%).